Applicant, as named in the Orange Book
Janssen Prods
Next listed expiry: Prezista on 26 Jun 2027. 7 products with live protection, 1 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Prezista NDA 021976 · 4 strengths darunavir | 26 Jun 2027 patent |
| Prezista NDA 202895 darunavir | 26 Jun 2027 patent |
| Edurant NDA 202022 rilpivirine hydrochloride | 15 Sep 2027 exclusivity |
| Yondelis NDA 207953 trabectedin | 7 Jul 2028 patent |
| Prezcobix NDA 205395 · 2 strengths cobicistat; darunavir ethanolate | 6 Oct 2032 patent |
| Edurant Ped NDA 219016 rilpivirine hydrochloride | 23 Oct 2037 patent |
| Symtuza NDA 210455 cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | 19 Jul 2038 patent, carve-out possible |
Recent events
- Edurant · First generic approved · ANDA 218798, Somerset Theraps LlcApproved 29 Jan 2026Detected 25 Oct 2026
- Edurant · Generic approved · ANDA 218798, Somerset Theraps LlcApproved 29 Jan 2026Detected 25 Oct 2026
- Edurant · Generic approved · ANDA 219788, LaurusApproved 10 Jul 2026Detected 25 Oct 2026
- Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
- Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
- Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
- Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
- Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
- Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
- Edurant · Enters 12-month window basis: exclusivityListed date 15 Sep 2027Detected 24 Oct 2026
- Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
Products without listed protection (1)
| Drug | Earliest generic entry |
|---|---|
| Prezcobix Ped NDA 220092 cobicistat; darunavir ethanolate | open now no listed protection |